Full profile
| Also known as | Neumentix, Mentha spicata |
|---|---|
| Best for | Working memory support · Attention support |
| Evidence grade | Grade C — Limited — early or small human trials |
| Studied dose range | 900 mg/day of standardized extract. |
| Time to effect | Acute attention signal within hours; working-memory benefit studied over 90 days. |
| Best form | Neumentix, standardized to roughly 14.5–24% total phenolics including rosmarinic acid. |
Evidence, honestly graded
Downgraded from B to C on 2026-07-11 for sponsor-dependence. Both supporting trials are Kemin-funded (the Neumentix developer): Herrlinger 2018 (J Altern Complement Med), a 90-day RCT in adults with age-associated memory impairment — not a broad healthy-adult population — and the Falcone 2018 follow-up acute-attention trial (PMC6291964). With no manufacturer-independent replication, a pivotal trial in the wrong population, and effect sizes near the threshold of clinical meaningfulness, the honest grade is C.
See the full grading rubric — study type, replication, population match, and dose adequacy — in The Evidence Standard.
73 licensed natural health products in Health Canada's LNHPD list Spearmint Extract as a medicinal ingredient.
That makes Spearmint Extract a recognized, licensable medicinal ingredient in Canada — regulated by Health Canada's Natural and Non-prescription Health Products Directorate, which issues each licensed natural health product a Natural Product Number (NPN). Search the LNHPD to verify.
Side effects
- Generally well tolerated
Who should avoid it or check first
- Pregnant or breastfeeding without clinician guidance (limited data)
Interactions
- No material known interactions
Stacks well with
What to look for on a label
- Specify the branded Neumentix extract and its phenolic standardization — plain spearmint extract doesn't guarantee the studied material.
References
- Herrlinger 2018, J Altern Complement Med — Neumentix 90-day RCT. Adults with age-associated memory impairment; 90-day dosing improved working memory versus placebo, with a follow-up acute-attention trial. PMID 29314866. Kemin-funded; educational, not a product claim.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
Revision history
Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.
- 2026-07-11Grade changeGrade B → Grade C
Downgraded from B to C. The working-memory effect is real in the trials that exist but rests on a single branded extract with limited independent replication.
See how Spearmint Extract compares on grade, dose, and goal in the Evidence Explorer.
